(Q53556772)

English

Economics, health-related quality of life, and cost-effectiveness methods for the TACTICS (Treat Angina With Aggrastat [tirofiban]] and Determine Cost of Therapy with Invasive or Conservative Strategy)-TIMI 18 trial.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

15 May 2018

http://europepmc.org/abstract/MED/10072215

Economics, health-related quality of life, and cost-effectiveness methods for the TACTICS (Treat Angina With Aggrastat [tirofiban]] and Determine Cost of Therapy with Invasive or Conservative Strategy)-TIMI 18 trial. (English)

1 reference

Europe PubMed Central

15 May 2018

http://europepmc.org/abstract/MED/10072215

quality of life

1 reference

based on heuristic

inferred from title

Harlan M. Krumholz

10

object named as

Krumholz H

1 reference

Europe PubMed Central

15 May 2018

Stephen G. Ellis

11

object named as

Ellis SG

1 reference

Europe PubMed Central

15 May 2018

author name string

Weintraub WS

1

1 reference

Europe PubMed Central

15 May 2018

http://europepmc.org/abstract/MED/10072215

Culler SD

2

1 reference

Europe PubMed Central

15 May 2018

http://europepmc.org/abstract/MED/10072215

Kosinski A

3

1 reference

Europe PubMed Central

15 May 2018

http://europepmc.org/abstract/MED/10072215

Becker ER

4

1 reference

Europe PubMed Central

15 May 2018

http://europepmc.org/abstract/MED/10072215

Mahoney E

5

1 reference

Europe PubMed Central

15 May 2018

http://europepmc.org/abstract/MED/10072215

Burnette J

6

1 reference

Europe PubMed Central

15 May 2018

http://europepmc.org/abstract/MED/10072215

Spertus JA

7

1 reference

Europe PubMed Central

15 May 2018

http://europepmc.org/abstract/MED/10072215

Feeny D

8

1 reference

Europe PubMed Central

15 May 2018

http://europepmc.org/abstract/MED/10072215

Cohen DJ

9

1 reference

Europe PubMed Central

15 May 2018

http://europepmc.org/abstract/MED/10072215

Demopoulos L

12

1 reference

Europe PubMed Central

15 May 2018

http://europepmc.org/abstract/MED/10072215

Robertson D

13

1 reference

Europe PubMed Central

15 May 2018

http://europepmc.org/abstract/MED/10072215

Boccuzzi SJ

14

1 reference

Europe PubMed Central

15 May 2018

http://europepmc.org/abstract/MED/10072215

Barr E

15

1 reference

Europe PubMed Central

15 May 2018

http://europepmc.org/abstract/MED/10072215

Cannon CP

16

1 reference

Europe PubMed Central

15 May 2018

http://europepmc.org/abstract/MED/10072215

language of work or name

0 references

publication date

1 February 1999

1 reference

Europe PubMed Central

15 May 2018

http://europepmc.org/abstract/MED/10072215

American Journal of Cardiology

1 reference

Europe PubMed Central

15 May 2018

http://europepmc.org/abstract/MED/10072215

83

1 reference

Europe PubMed Central

15 May 2018

http://europepmc.org/abstract/MED/10072215

317-322

1 reference

Europe PubMed Central

15 May 2018

http://europepmc.org/abstract/MED/10072215

3

1 reference

Europe PubMed Central

15 May 2018

http://europepmc.org/abstract/MED/10072215

Economic assessment of low-molecular-weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients: results from the ESSENCE randomized trial. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q wave Coronary Even

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900860-1

7 January 2021

Cost-effectiveness of streptokinase for acute myocardial infarction: A combined meta-analysis and decision analysis of the effects of infarct location and of likelihood of infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900860-1

7 January 2021

Cost effectiveness of thrombolytic therapy with streptokinase in elderly patients with suspected acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900860-1

7 January 2021

Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900860-1

7 January 2021

Analysis of the relative costs and effectiveness of primary angioplasty versus tissue-type plasminogen activator: the Primary Angioplasty in Myocardial Infarction (PAMI) trial. The PAMI Trial Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900860-1

7 January 2021

A cost-effective analysis of primary coronary angioplasty versus thrombolysis for acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900860-1

7 January 2021

Cost and quality of life: thrombolysis and primary angioplasty

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900860-1

7 January 2021

Costs and effectiveness of routine therapy with long-term beta-adrenergic antagonists after acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900860-1

7 January 2021

Cost-effectiveness of captopril therapy after myocardial infarction.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900860-1

7 January 2021

Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. Scandinavian Simvastatin Survival Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900860-1

7 January 2021

Economic evaluation of cardiac rehabilitation soon after acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900860-1

7 January 2021

Cost-effectiveness of a smoking cessation program after myocardial infarction.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900860-1

7 January 2021

Economic assessment of platelet glycoprotein IIb/IIIa inhibition for prevention of ischemic complications of high-risk coronary angioplasty. EPIC Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900860-1

7 January 2021

Anxiety, depression, quality of life, and self-care among survivors of myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900860-1

7 January 2021

Depression following myocardial infarction. Impact on 6-month survival.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900860-1

7 January 2021

A comparison of the costs of and quality of life after coronary angioplasty or coronary surgery for multivessel coronary artery disease. Results from the Emory Angioplasty Versus Surgery Trial (EAST).

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900860-1

7 January 2021

A study on the cost-effectiveness of coronary revascularization: introducing the simultaneous mimic health status model.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900860-1

7 January 2021

Estimating Physicians' Work for a Resource-Based Relative-Value Scale

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900860-1

7 January 2021

Monitoring the quality of life in patients with coronary artery disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900860-1

7 January 2021

Identifiers

10.1016/S0002-9149(98)00860-1

1 reference

Europe PubMed Central

15 May 2018

http://europepmc.org/abstract/MED/10072215

1 reference

Europe PubMed Central

15 May 2018

http://europepmc.org/abstract/MED/10072215

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53556772&oldid=1371368961"